Literature DB >> 20147814

CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.

Cameron Y S Lee1, Jon B Suzuki.   

Abstract

Biochemical markers of bone metabolism have been used in medicine to evaluate and provide treatment to patients with metabolic bone diseases, such as osteoporosis. Serum cross-linked C-telopeptide of type I collagen (CTX) is a marker of osteoclast activity and is used to assess the level of bone resorption. Recently, in oral and maxillofacial surgery, it was proposed that the levels of serum CTX may predict the subsequent risk of developing osteonecrosis of the jaws (ONJ) after oral surgery procedures for patients taking oral bisphosphonates (BPs). The goal of this study was to determine whether this specific serum marker of bone resorption could preoperatively predict the risk of developing ONJ from oral BPs.We hypothesized that there is no clinical correlation between the observed preoperative serum CTX values and the risk of developing ONJ. The authors examine the scientific basis (validity) of the morning fasting serum CTX test in 163 consecutive patients who underwent various oral surgery procedures in the office. The authors also review the laboratory test results and the recommended protocol based on the test values. One hundred sixty-three patients (mean age, 75.9 years) were divided into 2 groups. Group I was the control group that consisted of 109 patients taking oral BPs who did not take the CTX test preoperatively. Group 2 consisted of 54 patients taking BPs and who elected to have the CTX test performed to assess their level of risk of developing ONJ, preoperatively. Both groups of patients were observed for a period of 8 weeks for signs and symptoms of BP-associated ONJ after surgery. The clinical data at 8 weeks and beyond revealed that there was no evidence of BP-associated ONJ in all participants. We conclude that the serum CTX is not a valid preoperative test to accurately assess the level of risk of developing ONJ and is not indicated in the oral surgery patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147814     DOI: 10.1097/ID.0b013e3181cec8bc

Source DB:  PubMed          Journal:  Implant Dent        ISSN: 1056-6163            Impact factor:   2.454


  15 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

2.  Comparison of BALP, CTX-I, and IL-4 levels around miniscrew implants during orthodontic tooth movement between two different amounts of force.

Authors:  Mine Gecgelen Cesur; V Ozgen Ozturk; Beral Afacan; F Burcu Sirin; Afra Alkan; Torun Ozer
Journal:  Angle Orthod       Date:  2019-02-07       Impact factor: 2.079

3.  Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.

Authors:  Sung Jin Bae; Beom-Jun Kim; Kyeong Hye Lim; Seung Hun Lee; Hong Kyu Kim; Ghi Su Kim; Jung-Min Koh
Journal:  J Bone Miner Metab       Date:  2012-05-19       Impact factor: 2.626

4.  Tissue-specific biomarkers in gingival crevicular fluid are correlated with external root resorption caused by constant mechanical load: an in vivo study.

Authors:  Gui-Yue Huang; Sung-Hwan Choi; Hwi-Dong Jung; Hyun Sil Kim; Chung-Ju Hwang; Kee-Joon Lee
Journal:  Clin Oral Investig       Date:  2021-04-06       Impact factor: 3.573

Review 5.  Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Authors:  Mohamed E Awad; Christina Sun; Joshua Jernigan; Mohammed Elsalanty
Journal:  J Am Dent Assoc       Date:  2019-06-28       Impact factor: 3.634

Review 6.  Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Bassel Traboulsi-Garet; Adrià Jorba-García; Octavi Camps-Font; Fabio Abreu Alves; Rui Figueiredo; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2022-02-06       Impact factor: 3.573

7.  Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors:  Christian Thomas; Magdalena Spanidis; Christina Engel; Frederik C Roos; Sebastian Frees; Andreas Neisius; Christian Hampel; Peter Rubenwolf; Joachim W Thüroff; Christian Walter; Matthias Miederer
Journal:  Clin Oral Investig       Date:  2015-08-26       Impact factor: 3.573

8.  The relationship between implant stability and bone health markers in post-menopausal women with bisphosphonate exposure.

Authors:  Pamela Taxel; Denise Ortiz; David Shafer; David Pendrys; Susan Reisine; Kandasamy Rengasamy; Martin Freilich
Journal:  Clin Oral Investig       Date:  2013-03-16       Impact factor: 3.573

9.  [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].

Authors:  B Svejda; Ch Muschitz; R Gruber; Ch Brandtner; Ch Svejda; R W Gasser; G Santler; H P Dimai
Journal:  Wien Med Wochenschr       Date:  2016-02

10.  Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study.

Authors:  Martin Salgueiro; Michael Stribos; Li Fang Zhang; Mark Stevens; Mohamed E Awad; Mohammed Elsalanty
Journal:  EPMA J       Date:  2019-01-24       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.